2-(1-Isopropyl-3-piperidinyl)acetic acid | 1220030-63-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-(1-Isopropyl-3-piperidinyl)acetic acid
• 英文别名: 2-(1-propan-2-ylpiperidin-3-yl)acetic acid
• CAS: 1220030-63-6
• 化学式: C₁₀H₁₉NO₂
• mdl: MFCD13563012
• 分子量: 185.26
• InChiKey: LPSCOVATVMOUAT-UHFFFAOYSA-N

物化性质

• 沸点：
  294.7±13.0 °C(Predicted)
• 密度：
  1.018±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

文献信息

• DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US20150152096A1

  公开（公告）日：2015-06-04

  Provided herein are dihydropyrimidine compounds and their pharmaceutical applications, especially for use in treating and preventing HBV diseases. Specifically, provided herein are compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is the use of the compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof for treating and preventing HBV diseases.

  本文提供了二氢嘧啶化合物及其药物应用，特别用于治疗和预防HBV疾病。具体来说，本文提供了具有化学式（I）或（Ia）的化合物，或其对映体、二对映异构体、互变异构体、水合物、溶剂合物或其药学上可接受的盐，其中化学式的变量如规范中所定义。本文还提供了利用具有化学式（I）或（Ia）的化合物，或其对映体、二对映异构体、互变异构体、水合物、溶剂合物或其药学上可接受的盐来治疗和预防HBV疾病。
• Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
  申请人：LegoChem Biosciences, Inc.

  公开号：US10961242B2

  公开（公告）日：2021-03-30

  The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.

  本发明涉及作为自体毒素抑制剂的新型化合物，用于治疗和预防由自体毒素激活或溶血磷脂酸浓度升高引起的病症或紊乱，以及含有本发明的药物组合物。 本发明的新型化合物是自体毒素抑制剂，通过抑制溶血磷脂酸的产生，可用于治疗或预防心血管疾病、癌症、代谢紊乱、肾脏疾病、肝脏疾病、炎症性疾病、神经系统疾病、呼吸系统疾病、纤维化疾病、眼部疾病、胆汁淤积性和其他形式的慢性瘙痒症，或急性或慢性器官移植排斥反应。
• Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer
  申请人：Lead Discovery Center GmbH

  公开号：US11111238B2

  公开（公告）日：2021-09-07

  The invention provides novel coumarin derivatives as specific mitochondrial RNA polymerase inhibitors for the treatment of cancer.

  本发明提供了新型香豆素衍生物，作为治疗癌症的特异性线粒体 RNA 聚合酶抑制剂。
• NOVEL COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
  申请人：LegoChem Biosciences, Inc.

  公开号：US20200172542A1

  公开（公告）日：2020-06-04

  The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.
• COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER
  申请人：Lead Discovery Center GmbH

  公开号：US20200291011A1

  公开（公告）日：2020-09-17

  The invention provides novel coumarin derivatives as specific mitochondrial RNA polymerase inhibitors for the treatment of cancer.